Compare WPRT & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WPRT | IXHL |
|---|---|---|
| Founded | 1995 | 2001 |
| Country | Canada | Australia |
| Employees | 112 | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.8M | 37.0M |
| IPO Year | 2006 | 2024 |
| Metric | WPRT | IXHL |
|---|---|---|
| Price | $1.85 | $3.81 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.38 | N/A |
| AVG Volume (30 Days) | 23.6K | ★ 235.8K |
| Earning Date | 04-23-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $28.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.54 | $0.16 |
| 52 Week High | $4.14 | $6.39 |
| Indicator | WPRT | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 33.56 | 55.82 |
| Support Level | $1.71 | $0.33 |
| Resistance Level | $1.85 | $5.08 |
| Average True Range (ATR) | 0.06 | 0.32 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 10.68 | 73.10 |
Westport Fuel Systems Inc is an organization engaged in the engineering, manufacturing, and supply of alternative fuel systems and components for transportation applications. It has three reportable segments: High-Pressure Controls, Heavy-Duty OEM, and Cespira. It derives maximum revenue from Heavy-Duty OEM segment. Heavy-Duty OEM segment's products include HPDI related fuel system solutions and components. Geographically, the company operates in Europe, America and Asia, of which it generates maximum revenue from Europe. It also develops and supplies advanced LPG, CNG, LNG and H2 systems and components for OEM (original equipment manufacturer) D-OEM (delayed oem) and After Market (retrofit market) world-wide.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.